Vanguard Portfolio Management’s Climb Bio CLYM Stock Holding History

Vanguard Portfolio Management’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.13M	Buy	+239,657	New	+$2.48M	﹤0.01%	2588

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management's CLYM Position: Q2 2026 in Review

Vanguard Portfolio Management opened a new position in Climb Bio (CLYM) in Q2 2026: 239,657 shares worth $3.13M. The stake represents ﹤0.01% of the portfolio and ranks #2588 among its holdings.

108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

Vanguard Portfolio Management held 239,657 shares of Climb Bio worth $3.13M as of Q2 2026.
Climb Bio was a new Vanguard Portfolio Management position in Q2 2026.
Climb Bio made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2588 holding.
108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.